Ulrich Sterz Selected Research

Disseminated Intravascular Coagulation

3/2024

Tocilizumab administration in cytokine release syndrome is associated with hypofibrinogenemia after chimeric antigen receptor T-cell therapy for hematologic malignancies.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ulrich Sterz Research Topics

Disease

1	Disseminated Intravascular Coagulation 03/2024
1	Cytokine Release Syndrome 03/2024
1	Liver Diseases (Liver Disease) 03/2024
1	Hematologic Neoplasms (Hematological Malignancy) 03/2024
1	Acute-Phase Reaction 03/2024
1	Osteosarcoma (Osteogenic Sarcoma) 01/2021
1	Neoplasm Metastasis (Metastasis) 01/2021
1	Neoplasms (Cancer) 01/2021
1	Pneumonia (Pneumonitis) 01/2021
1	Sarcoma (Soft Tissue Sarcoma) 01/2021
1	Disease Progression 01/2021
1	Microsatellite Instability 01/2021
1	Cardiac Arrhythmias (Arrythmia) 01/2017
1	ST Elevation Myocardial Infarction 01/2017

Drug/Important Bio-Agent (IBA)

1	tocilizumab (atlizumab)FDA Link 03/2024
1	Fibrinogen (Factor I)FDA Link 03/2024
1	Blood Coagulation Factors (Coagulation Factor)IBA 03/2024
1	Dacarbazine (DIC)FDA LinkGeneric 03/2024
1	Chimeric Antigen ReceptorsIBA 03/2024
1	IpilimumabIBA 01/2021
1	Docetaxel (Taxotere)FDA Link 01/2021
1	NivolumabIBA 01/2021
1	Gemcitabine FDA Link 01/2021
1	B7-H1 AntigenIBA 01/2021

Therapy/Procedure

3	Therapeutics 03/2024 - 01/2021
1	Drug Therapy (Chemotherapy) 01/2021
1	Combined Modality Therapy 01/2021
1	Immunotherapy 01/2021
1	Percutaneous Coronary Intervention 01/2017